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Abstract
There is a critical shortage in the number of deceased human organs that become available for 
purposes of clinical transplantation. This problem might be resolved by the transplantation or 
organs from pigs genetically-engineered to protect them from the human immune response. The 
pathobiological barriers to successful pig organ transplantation in primates include activation of 
the innate and adaptive immune systems, coagulation dysregulation, and inflammation. Genetic 
engineering of the pig as an organ source has increased the survival of the transplanted pig heart, 
kidney, islet and corneal graft in nonhuman primates (NHP) from minutes to months or 
occasionally years. Genetic engineering may also contribute to any physiological barriers that 
might be identified as well as to reducing the risks of transfer of a potentially infectious micro-
organism with the organ. There are now an estimated 40 or more genetic alterations that have been 
carried out in pigs, with some pigs expressing 5 or 6 manipulations. With the new technology now 
available, it will become increasingly common for a pig to express even more genetic 
manipulations, and these could be tested in the pig-to-NHP models to assess their efficacy and 
benefit. It is therefore likely that clinical trials of pig kidney, heart, and islet transplantation will 
become feasible in the near future.
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Introduction
The current issue of this journal is directed towards animal models of human disease. This 
present review is not strictly on this topic, but it is in the closely-related field of genetically-
engineering a large animal to overcome pathobiological barriers that currently prevent cross-
species organ or cell transplantation.
There is a critical shortage in the number of deceased human organs that become available 
for purposes of clinical transplantation. For example, in the USA alone, there are currently 
more than 124,000 patients waiting for transplant and yet only approximately 28,000 organ 
transplants are carried annually using organs from deceased donors. Despite enormous 
efforts over the past 50 years, this problem has not been resolved, and in fact is increasing. 
This is despite the fact that transplant surgeons have liberalized their criteria for selection of 
the donor; they now use organs from what are termed ‘high risk’, ‘marginal’, or ‘extended 
criteria’ deceased donors, which are organs from less-than-ideal donors that would not have 
been used a few years ago. Furthermore, organs from living donors are increasingly being 
used. With regard to kidney donation, the risk to the living donor is small, though there are 
some small long-term detrimental sequelae. With regard to donors of partial livers, there is a 
significant risk of both mortality and morbidity. We are, therefore, putting healthy altruistic 
humans at some risk in an effort to provide organs for those with end-stage organ failure [1].
Background
Throughout the 20th century, there were attempts to use animals as sources of organs for 
clinical transplantation [2,3]. These generally involved non-human primates (NHPs), 
although a few efforts were made using non-primate mammals. In these latter cases, graft 
survival was extremely short, often measured in minutes, rather than hours or days. 
Transplantation between immunologically ‘discordant’ species, e.g., pig-to-human, therefore 
represents a major immunological barrier. However, it was soon realized that NHPs would 
not be the ideal source of organs or cells for clinical transplantation. Therefore, during the 
latter part of the 20th century, attention was directed towards using the pig as the potential 
source of organs and cells. The pig has a number of advantages in this respect although the 
immunological barriers are far greater than those associated with NHP species.
Without the genetic-engineering of pigs to protect their organs and cells from the primate’s 
immune response, little progress would have been made. The transplantation of organs from 
wild-type (genetically-unmodified) pigs into NHPs (or even humans) resulted in rapid 
antibody-dependent complement-mediated rejection (hyperacute rejection) (Figures 1 and 
2), similar to that which occurs when an ABO-incompatible allograft is transplanted 
between humans. In allotransplantation, hyperacute rejection may also result when the 
recipient is sensitized to donor human leukocyte antigens (HLA, i.e., has a high level of 
panel-reactive antibodies [PRA]). The standard pharmacologic immunosuppressive therapy 
administered to prolong allograft survival has no or little effect in protecting pig organs from 
hyperacute rejection.
As the identity of the antigens on the vascular endothelium of the pig organ was unknown in 
the 1980s, efforts were made to prolong graft survival by removing all immunoglobulins 
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(which included anti-pig antibodies) from the recipient blood by plasmapheresis [4]. The 
temporary removal of immunoglobulins (antibodies) directed to ABO blood group antigens 
had indeed proved successful in allowing permanent ABO-incompatible allograft survival 
[5–7], and so it was hoped that this approach might also suffice in xenotransplantation [8,9]. 
As the pathobiological differences between pig and primate are so much more complex than 
between ABO-incompatible primates, this proved not to be the case. The continuing 
production of anti-pig antibodies resulted in graft destruction (a form of rejection variously 
termed acute humoral xenograft rejection [AHXR], delayed xenograft rejection, or acute 
vascular rejection).
Gal antigen expression in pigs
A major step forward was taken when the major carbohydrate antigen on pig vascular 
endothelial cells, against which humans have anti-pig antibodies, was identified as 
galactose-α1,3-galactose (Gal) (reviewed in [10]). This resulted in efforts to remove 
specifically anti-Gal antibodies from the potential recipient using either immunoadsorption 
with immunoaffinity columns of synthetic Gal oligosaccharides or by the intravenous 
infusion of the Gal oligosaccharides (which were then bound by anti-Gal antibodies, and the 
resulting antigen-antibody complexes excreted) (reviewed in [11] and [12]). These 
approaches proved no more successful than plasmapheresis. Although delaying graft 
rejection, they were not associated with truly prolonged graft survival even when combined 
with immunosuppressive therapy that prevented a T cell-dependent elicited antibody 
response.
Pig genetic engineering to control human complement-mediated injury
Attention then turned to genetic engineering to try to overcome these barriers. The first 
approach was directed towards protecting the graft from the effects of primate complement. 
When the complement cascade is activated in humans, for example in response to the 
presence of pathogenic bacteria in the blood, complement activation generally does not 
damage the host’s tissues. This is because of the expression of human complement-
regulatory proteins (CRPs) on the surface of vascular endothelial cells. Pigs have similar 
CRPs, but these are relatively inefficient at protecting the pig cells from human 
complement-mediated injury [13]. It was therefore suggested that pigs should be 
genetically-manipulated to introduce transgenes for human CRPs, of which there are several 
(e.g., CD46, CD55, CD59).
At least two independent groups made this original suggestion [14,15], and the first pig 
expressing a human CRP (CD55, decay-accelerating factor), produced by microinjection of 
DNA directly into the pronucleus of a fertilized egg, was born in the early 1990s (Table 1) 
[16–19]. The U.K. group of White and his colleagues performed numerous studies in the 
pig-to-baboon or pig-to-monkey model and demonstrated that the expression of CD55 
prolonged pig heart and kidney graft survival to days or weeks (reviewed in [11]). This was 
the first demonstration of the benefit of genetically-engineering the pig in overcoming the 
barriers of xenotransplantation. However, this manipulation alone did not enable truly long-
term graft survival.
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Pig genetic engineering to delete Gal antigens
When it became possible to delete a gene from a pig, which was not possible until nuclear 
transfer (cloning) technology was introduced [20,21], efforts were made to delete the gene 
for the enzyme that attaches the terminal Gal saccharides to the underlying carbohydrates on 
the pig vascular endothelium [22–24]. Nuclear transfer was combined with homologous 
recombination technology, and the resulting α1,3-galactosyltransferase gene-knockout 
(GTKO) pigs were then used as sources of organs for experimental transplantation in NHPs. 
In baboons selected for low levels of the remaining anti-pig antibodies (so-called anti-
nonGal antibodies), the transplantation of GTKO pig hearts and kidneys prolonged graft 
survival significantly [25–30].
The transplantation of organs from GTKO/hCRP pigs had a further beneficial effect over 
GTKO or CRP alone [31–33].
Coagulation dysregulation
However, vascular endothelial cell activation by anti-nonGal antibodies (the antigenic 
targets of which were unknown) (or by anti-Gal antibodies), complement deposition, and the 
activation of the endothelium by innate immune cells (e.g., neutrophils, monocytes, 
macrophages) resulted in the development of a thrombotic microangiopathy and graft failure 
(Figure 3) [25,30,34]. This was a result of fibrin deposition and platelet aggregation in the 
vessels of the graft, which, when advanced (i.e., when all the recipient coagulation factors 
had been exhausted) could result in a consumptive coagulopathy. This lead to spontaneous 
bleeding (e.g., in the gastrointestinal tract) and could be fatal [25,35–37]. Excision of the 
graft reversed this process, confirming that it was the changes taking place in the graft that 
was the source of the problem.
This development of thrombotic microangiopathy from vascular endothelial activation was 
enhanced by molecular incompatibilities in the coagulation systems between pig and 
primate. For example, pig tissue factor pathway inhibitor does not successfully inhibit 
primate factor Xa, pig thrombomodulin does not catalyze primate protein C, and pig von 
Willebrand factor is associated with excessive primate platelet aggregation. The mechanism 
is complicated in that not only do the activated porcine endothelial cells express high levels 
of tissue factor (a procoagulant molecule) and increased tissue factor activity, but direct 
exposure of primate platelets and monocytes to porcine endothelial cells results in increased 
tissue factor activity on these primate structures also [37]. Coagulation-anticoagulation 
dysregulation of relevance to xenotransplantation has been discussed previously by several 
authors [38–40].
Pig genetic engineering to correct coagulation dysfunction
It was therefore determined that the pig should be genetically-engineered to protect it from 
these coagulation discrepancies [41]. As with CRPs, efforts were made to introduce 
transgenes of human coagulation regulatory proteins (e.g., thrombomodulin, endothelial 
protein C receptor, tissue factor pathway inhibitor, CD39, CD73) [42–45]. An alternative 
approach is to reduce expression of tissue factor by small interfering RNA [46].
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Multi-gene transgenic pigs have been produced that express not only GTKO and CRPs, but 
multiple anticoagulant transgenes, including various combinations of thrombomodulin, 
endothelial protein C receptor, tissue factor pathway inhibitor, and CD39 [41]. The 
expression of one or more human coagulation-regulatory proteins increases graft survival 
further. For example, in pig heterotopic heart transplantation (i.e., non-life-supporting 
grafts), grafts have beat strongly for more than one or even two years [47–49]. After 
orthotopic heart transplantation, where the pig heart actually replaces the NHP heart and is 
therefore entirely responsible for support of the circulation, recipient survival has been 
approximately 2 months (but the demise of the recipient has more commonly been related to 
complications in the management of the animal than to graft failure) (reviewed in [12]). 
With pig life-supporting kidney transplantation, survival has been for >6 months in at least 
one recipient animal [50,51].
McGregor and his colleagues have demonstrated that increased immunosuppressive therapy, 
thus reducing the immune activation of the pig vascular endothelium, is at least as effective 
as the administration of anticoagulant agents in delaying the development of thrombotic 
microangiopathy [52–54]. This adds support to the conclusion that the development of this 
complication is primarily related to immune activation and injury of the endothelium. 
Nevertheless, since at present immune activation of the vascular endothelial cells cannot be 
totally prevented, reducing the problem by correcting the coagulation dysfunction between 
pig and primate provides an alternative approach towards a solution and may even be 
essential when there is no immune response.
NonGal antigen expression in pigs
Efforts have been made to identify the structure of nonGal antigens. It has been known since 
the 1990s that pigs express N-glycolylneuraminic acid (NeuGc), which is not expressed in 
humans, although it is expressed in all apes and Old World monkeys [55]. As humans do not 
express NeuGc, they make anti-NeuGc antibodies, just as they make anti-Gal antibodies 
(reviewed in [56]). It has therefore been predicted for many years that expression of NeuGc 
might be a factor when clinical xenotransplantation is carried out even if the donor organs 
are from GTKO pigs. However, NeuGc does not play a role in the experimental laboratory 
model as both pigs and NHPs express this saccharide, and therefore anti-NeuGc antibodies 
are not involved in the immune response.
Recently, pigs that express neither Gal nor NeuGc have been produced [57,58]. In vitro 
studies using human serum have demonstrated that there is reduced human antibody binding 
to cells from these GTKO/NeuGcKO pigs compared to binding to GTKO pig cells [59]. It is 
therefore likely to be important to utilize organs from pigs that express neither Gal nor 
NeuGc (i.e., GTKO/NeuGcKO pigs) for clinical organ xenotransplantation.
A second nonGal antigenic target for primate anti-pig antibodies has recently been 
identified, β1,4 N-acetylgalactosaminyltransferase [60]. Baboons have pre-formed 
antibodies to this glycan, as do most humans [59]. There is preliminary evidence that the 
absence of this antigen on pig cells also reduces human serum antibody binding [59]. As this 
antigen (like Gal) is not expressed in NHPs, the pig-to-NHP model will be valuable in 
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determining the relative importance of its effect. This pig antigen may also need to be 
deleted in pigs used as organ-sources in clinical trials of xenotransplantation. Tector’s group 
has produced pigs that express neither Gal, NeuGc, nor β1,4 N-
acetylgalactosaminyltransferase [59]. In vitro evidence therefore suggests that pigs that do 
not express NeuGc or Gal (and possibly β1,4 N-acetylgalactosaminyltransferase), but do 
express one or more human CRPs and one or more human coagulation-regulatory proteins 
that (AQ: as intended?) may be beneficial for clinical xenotransplantation.
Pig genetic engineering to suppress the inflammatory response
There are other genetic modifications that may provide further benefit. For example, there is 
increasing evidence that a primate inflammatory response to pig grafts is playing a 
significant role in graft failure, a condition that Ezzelarab has called a ‘systemic 
inflammatory response in xenograft recipients’ (SIXR) [61,62]. It is known that 
interleukin-6 (IL-6) plays a significant role in this response, but other cytokines and 
chemokines are also involved. It may therefore be beneficial to develop pigs that are 
transgenic for one or more human anti-inflammatory gene(s), e.g., hemeoxygenase-1 or 
A20. Transgenic pigs expressing either A20 or HO1 are available [63–65], and these have 
recently become available on a GTKO/hCRP background (Ayares D, unpublished). While 
there is preliminary evidence, from ex vivo organ perfusion experiments, of a functional 
effect of these transgenes, it has not yet been clarified in vivo.
The adaptive (T cell) immune response
Whatever genetically-engineered pig is used as the organ source, the NHP recipient will 
develop a T cell-dependent (adaptive) immune response that will lead to graft infiltration 
with T cells and other immune cells as well as a major increase in elicited anti-pig (largely 
IgG) antibodies. This response will inevitably result in graft rejection [66]. Therefore, an 
effective immunosuppressive regimen has to be administered to the recipient animal to 
prevent this response. The standard pharmacologic immunosuppressive agents, for example 
tacrolimus, cyclosporine, mycophenolate mofetil, rapamycin, even when employed in 
combinations that are effective in controlling allotransplant rejection, are not particularly 
successful in xenotransplantation, unless given in high doses that are inevitably associated 
with an increase in complications, particularly infection [67,68]. Newer agents that prevent 
T cell costimulation (and are therefore known as costimulation blockade agents) have 
proven more successful.
The initial agent (directed towards blocking the CD40/CD154 costimulation pathway) was 
an anti-CD154 monoclonal antibody (mAb), first introduced into xenotransplantation studies 
by Buhler and colleagues in 2000 [69]. This proved particularly effective in preventing an 
elicited antibody response, but has been shown to be associated with some thrombogenic 
effects (both in xenotransplantation and allotransplantation) and therefore may not be 
available for clinical use. An alternative is an anti-CD40 mAb, that also inhibits the CD40/
CD154 costimulation pathway, and this has been associated with excellent results, 
particularly by the groups of Mohiuddin [47–49] and Iwase [51,70].
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An alternative costimulation pathway, namely the B7/CD28 pathway, can be blocked by 
commercially-available agents, such as CTLA4-Ig (abatacept) and a modified version 
(belatacept), but this has proved less successful. Belatacept prevents a T cell proliferative 
response to a pig graft in vivo, but it does not prevent an elicited antibody response [50,70–
72]. Ezzelarab has suggested that other mechanisms of inducing sensitization may be 
involved [61,73]. There may be a case for blockade of both the CD40/CD154 and B7/CD28 
pathways [70].
The less systemic immunosuppressive therapy that is administered to the recipient, then the 
less likelihood there will be of major complications related to this therapy. Attention is 
therefore being directed to protect the graft from the T cell response by genetic manipulation 
of the organ-source pig.
Pig genetic engineering to suppress the adaptive immune response
Surprisingly, but fortunately, genetic engineering of the organ-source pigs directed towards 
protection from the innate response in some cases also reduces the adaptive immune 
response [74]. Deletion of Gal antigens [75] or expression of a human CRP [76,77] 
significantly reduces the in vitro T cell response to pig cells, though the nature of the 
experiments is such that it is difficult to measure this in vivo.
The gene for CTLA4-Ig has been introduced into the pig; this was carried out successfully 
by Phelps and colleagues in 2009 [78] (AQ: please check your meaning has been retained). 
These pigs expressed CTLA4-Ig to such an extent that the levels of soluble CTLA4-Ig in the 
blood were on occasions many times higher than the therapeutic levels required after 
administration of the agent to a patient with an allograft. The genetic manipulation, 
therefore, had been extremely successful. However, once weaned from the sow, and thus no 
longer receiving immunoglobulin in the milk, these piglets became immunocompromised 
and susceptible to infection, precluding their survival to an age at which they could 
reproduce.
Since then, methods to express the transgene only in specific cell types have been 
developed, and pigs have been produced that express CTLA4-Ig only in the pancreatic islet 
beta cells [79,80], vascular endothelial cells, or in certain neuronal cells (that have been used 
to try to correct Parkinson-like condition in monkeys [81,82]. Whether expression confined 
to the endothelial cells of an organ graft or to the beta cells of the islets will be sufficient to 
protect the organ or islets from the adaptive immune response remains uncertain, although it 
is likely to have some beneficial effect and may allow reduced systemic immunosuppressive 
therapy to be administered. It is difficult to determine this in the current animal models of 
xenotransplantation.
An alternative approach has been to introduce a dominant-negative mutant major 
histocompatibility complex (MHC) class II transactivator gene that results in reduced 
expression of swine leukocyte antigen (SLA) class II on the vascular endothelium of the pig 
organs [83]. This has been clearly demonstrated to reduce the T cell response in vitro [84], 
and there is a report indicating a modest effect in vivo [72]. This would therefore hopefully 
allow a reduced intensity of systemic immunosuppressive therapy.
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Deletion by knockout of MHC class I expression in the pig has recently been achieved and 
its effect is being explored [85].
Over-expression of human CD47 in transgenic pigs, with potential for ‘immune cloaking’ 
that prevents macrophage activation and phagocytosis of CD47 transgenic pig cells, is also 
being tested [86]. It is possible that peripheral tolerance can be induced in the host if mixed 
hematopoietic chimaerism can be established using CD47 transgenic pig progenitor cells. 
Three-gene transgenic pigs (GTKO/CD46/CD47) have been generated that robustly express 
both CD46 and CD47 for use in ex vivo lung perfusion and in vivo lung transplantation NHP 
models (Phelps C, unpublished), as well as in pig-to-NHP studies of tolerance induction.
Natural killer cells also play a role in xenograft rejection [87–91], and here again genetic 
engineering of the pig (to express HLA-E and/or G and/or Cw3) may prevent this [92–99].
Pig genetic engineering to correct physiological incompatibilities
If problems related to the immune response can be completely resolved, then attention can 
be directed to whether pig organs will function normally in primate hosts. There have been 
few studies in this respect [100,101]. These indicate that some problems initially perceived 
to be related to physiological differences between pig and primate, were in fact related to the 
effects of the immune response. When the immune response had been adequately controlled, 
organ function remained normal.
For example, early pig kidney transplants were associated with high levels of proteinuria 
that resulted in hypoalbuminemia [27,100]. When protection from the immune response was 
increased by the genetic engineering of the pig, this complication was greatly reduced or not 
seen. The fact that heterotopic pig hearts have functioned well in NHPs for >12 months, and 
life-supporting hearts for almost 2 months, suggests that pig myocardial function will not be 
compromised in a primate host.
With regard to genetically-engineered pig islet transplantation in diabetic NHPs, 
normoglycemia has been maintained for >1 year, confirming that pig insulin (which has 
only one amino acid difference from human insulin, and was used therapeutically in diabetic 
patients for decades) will be sufficient to correct diabetes after clinical islet 
xenotransplantation [79,102].
Pig livers have only functioned in NHPs for periods of a few days (largely associated with 
specific coagulation problems that have been identified after pig liver transplantation, 
particularly relating to the phagocytosis of the host platelets by the pig vascular endothelial 
cells and Kupffer cells in the graft [103–105]. These problems are also being addressed by 
genetic engineering of the pigs [106,107]. However, observations have been made that 
indicate that pig coagulation factors are at least partially functional in NHPs [108].
Nevertheless, it is unlikely that all of the myriad products of a pig liver will be able to fulfil 
the requirements of a primate. This problem can also be resolved by genetic engineering of 
the pig. For example, if pig albumin is found to be inadequate in a human host, then the pig 
could be genetically manipulated to produce human albumin.
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Pig genetic engineering to ensure the safety of xenotransplantation
One final area that has received considerable attention over a number of years is the 
potential risk of transferring a porcine virus or micro-organism to the recipient of the graft 
and, of greater importance, the potential for that micro-organism to be transferred to close 
contacts of the recipient, e.g., family members, medical or nursing staff. This could provide 
a potential risk to the community, particularly as humans may not have a natural immunity 
to this microorganism. The organ-source pigs will be housed under isolation conditions and 
will be monitored closely, and so it will be known if they are carrying any potentially 
infectious micro-organisms that could cause problems in the transplant recipient. It should 
be noted that this is often not the case in allotransplantation when viruses or micro-
organisms are knowingly transferred (such as cytomegalovirus and Epstein-Barr virus), and 
on occasions may unknowingly be transferred, for example human immunodeficiency 
(HIV), West Nile, or rabies viruses.
Expert opinion is that, by breeding, housing, and management of the donor pigs in 
designated pathogen-free (DPF) indoor facilities, it should be possible to prevent all 
significant pathogenic micro-organisms from being transferred with the pig organ, though 
endogenous retroviruses may be one exception [109–111].
The genome of every human cell contains viruses and virus particles known as human 
endogenous retroviruses (HERVs). It is not believed that these have any pathogenic effect 
and do not play any role in diseases that develop in humans. Similarly, pig genomes contain 
porcine endogenous retroviruses (PERVs), which are also thought not to be associated with 
any disease process in pigs. Concern has been raised, however, that the transfer of PERVs to 
humans might be pathogenic, or that recombination between PERVs and HERVs may give 
rise to a new virus that may be pathogenic [111,112]. Current opinion is that PERVs are not 
likely to be pathogenic to humans, but it would be possible to prevent activation of these 
viruses by genetic engineering of the pig if it were deemed necessary. For example, PERV 
activation can be suppressed by small interfering RNA technology [113–115].
The present status of pig genetic engineering for xenotransplantation
Ten years ago, developing a pig with a single genetic modification was a prolonged process, 
involving either pronuclear injection to add genes or homologous recombination for gene-
knockout. Techniques by which this can be achieved more rapidly, including the addition of 
co-expressed strings of transgenes using multi-cistronic 2A technology, have been 
introduced [41].
Recently, new methodologies have been developed using gene editing nuclease technology, 
and it is now possible to produce pigs with multiple genetic modifications simultaneously 
(Table 1) [116,117]. The techniques of zinc finger nucleases (ZFNs) [118–120], 
transcription activator-like effector nucleases (TALENS) [121,122] and genome editing by 
RNA-guided endonucleases (also known as clustered regularly interspaced short 
palindromic repeat [CRISPR]-Cas [CRISPR-associated]) significantly increase gene-editing 
efficiency.
Cooper et al. Page 9
J Pathol. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
CRISPRs are short, directly-repeating nucleotide sequences that alternate with small unique 
DNA fragments acquired from invading bacteriophages or plasmids, and are transcribed into 
target-specific RNA. The CRISPRs hybridize and form a complex with Cas9 nuclease that 
recognizes and cleaves foreign genetic material matching the CRISPR-derived RNA [123]. 
This complex CRISPR/Cas9 system has been developed into an elegant genome editing tool 
that allows the rapid and efficient production of pigs with multiple genetic modifications 
[116,124–126], which is having an impact on developing new pigs for xenotransplantation.
Recent studies by Tector’s group have shown that it is possible to produce pigs in which 
there are variable genetic manipulations demonstrated in different members of the litter 
[58,59]. These piglets may demonstrate 1, 2, or 3 genetic manipulations, thus providing a 
range of piglets from the same sow that can be tested in vitro and in vivo. These new 
technologies have increased the speed at which pigs with multiple genetic manipulations can 
be produced, and have also reduced the costs. It is likely, therefore, that more rapid progress 
will be achieved in the genetic manipulation of pigs for the specific purposes of 
xenotransplantation.
However, the ability to introduce multiple genetic manipulations simultaneously could lead 
to increased difficulty in determining exactly which manipulation is essential and which 
superfluous. Obviously, if more than one manipulation has been introduced, it may be 
difficult to determine which genetic alteration promoted a beneficial outcome following 
transplantation of a pig organ into a NHP. Furthermore, some manipulations have already 
been shown to be lethal or detrimental to the pig’s health, and it remains unknown whether 
there will be a maximum number of manipulations that can be tolerated by a pig.
There are now an estimated 40 or more genetic manipulations that have been carried out in 
pigs (Table 2), with some pigs expressing 5 or 6 manipulations [70,79,80]. With the 
technology now available, it will become increasingly common for a pig to express even 
more genetic manipulations, and these could be tested in the pig-to-NHP models to assess 
their efficacy and benefit [127]. It is therefore very likely that progress will be rapid during 
the next few years, and clinical trials of pig kidney, heart, and islet transplantation will 
become feasible.
Clinical trials of xenotransplantation
There are already clinical trials taking place of encapsulated pig islet transplantation [128] 
and of pig corneal transplantation. In the former case, results have to date been 
disappointing, but pig corneal transplantation has shown encouraging results [129]. Organ 
transplantation will follow when there is sufficient evidence in NHPs of consistent survival 
of the recipients of a life-supporting graft for periods of 6 or 12 months in the absence of 
complications from over-intensive immunosuppression therapy. Consideration is already 
being given to the selection of potential patients for these early clinical trials.
For example, patients awaiting kidney allotransplants who have a high level of anti-HLA 
antibody (with panel reactive antibodies [PRA] that may be 100%, indicating that it would 
be exceedingly difficult to find a human donor against whom there will not be a high risk of 
hyperacute rejection) may be suitable candidates for an initial clinical trial of pig kidney 
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transplantation. Current limited evidence is that patients with a high PRA are at no greater 
risk of rejecting a pig graft than patients with a low level or no PRA [130–132]. 
Furthermore, there is limited evidence that, even if a patient with a pig graft became 
sensitized to pig antigens, this would not preclude him or her from undergoing a subsequent 
allotransplant if a suitable donor could be found [132–134].
Other potential patients include those who might be ‘bridged’ by a pig heart while they 
await a human heart, although left ventricular assist devices can support a patient for several 
months or even 1–2 years. In the case of patients with fulminant liver failure, however, there 
is no similar device to support them and they might benefit from bridging with a pig liver (if 
the coagulation problems referred to above can be overcome). In an emergency, a human 
liver can often become available within days, and bridging with a pig organ would be short-
term, but potentially life-saving.
Alternative approaches to resolving the shortage of deceased human organs for 
transplantation include regenerative medicine approaches, stem cell technology, and 
blastocyst complementation, which have been discussed elsewhere (135). None of these 
approaches has yet reached the stage of testing in NHPs, and so remain less advanced than 
xenotransplantation. Mechanical assist devices to support or replace a failing heart, 
however, are in a much more advanced state than xenotransplantation (135), though a 
biological heart will have some advantages.
Comment
In 1982, our senior colleague, Thomas Starzl, one of the great pioneers of 
allotransplantation, wrote, “History tells us that procedures which were inconceivable 
yesterday, and are barely achievable today, often become routine tomorrow.” We believe 
that, with the novel genetically-engineered pigs becoming available to us, clinical pig organ 
and cell transplantation, inconceivable only a few years ago, and barely achievable today, 
will become routine tomorrow. Indeed, allotransplantation will eventually become of 
historic interest only.
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Figure 1. 
Macroscopic appearance of a wild-type pig kidney immediately after transplantation and 
reperfusion in a baboon (A) and 10 minutes later when hyperacute rejection had occurred 
(B).
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Figure 2. 
Histopathology of hyperacute rejection in a wild-type pig heart graft. Complement-mediated 
injury associated with the binding of baboon natural preformed anti-pig antibodies to 
antigens expressed on the vascular endothelium of the pig organ results in intravascular 
thrombosis and interstitial haemorrhage. Acute humoral xenograft rejection, a delayed 
antibody-mediated response, is often, but not always, associated with the production of 
elicited antibodies, and has a similar histopathological appearance but possibly with the 
presence of rather more innate immune cells, such as macrophages and neutrophils. 
Reproduced with permission from Byrne GW, et al. Xenotransplantation 2013;20:292–307 
(AQ : ensure that this reference is cited in sequence in the References list and the correct 
citation [number] used in this legend.)
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Figure 3. 
Thrombotic microangiopathy in a GTKO pig heart graft. Occlusion of small vessels by 
fibrin deposition and platelet aggregation results in ischemic injury with replacement 
fibrosis.
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Table 1
Timeline for application of evolving techniques for genetic engineering of pigs employed in 
xenotransplantation
Year Technique
1992 Microinjection of randomly-integrating transgenes
2000 Somatic cell nuclear transfer (SCNT)
2002 Homologous recombination
2011 Zinc finger nucleases (ZFNs)
2013 Transcription activator-like effector nucleases (TALENs)
2014 CRISPR/Cas9*
*CRISPR/Cas9 = clustered randomly interspaced short palindromic repeats and the associated protein 9
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Table 2
Selected genetically-modified pigs currently available for xenotransplantation research
Complement regulation by human complement-regulatory gene expression
CD46 (membrane cofactor protein)
CD55 (decay-accelerating factor)
CD59 (protectin or membrane inhibitor of reactive lysis)
Gal or nonGal antigen ‘masking’ or deletion
Human H-transferase gene expression (expression of blood type O antigen)
Endo-beta-galactosidase C (reduction of Gal antigen expression)
α1,3-galactosyltransferase gene-knockout (GTKO)
Cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) gene-knockout (NeuGcKO)
β4GalNT2 (β1,4 N-acetylgalactosaminyltransferase) gene-knockout (β4GalNT2KO)
Suppression of cellular immune response by gene expression or downregulation
CIITA-DN (MHC class II transactivator knockdown, resulting in swine leukocyte antigen class II knockdown)
Class I MHC-knockout (MHC-IKO)
HLA-E/human β2-microglobulin (inhibits human natural killer cell cytotoxicity)
Human FAS ligand (CD95L)
Human GnT-III (N-acetylglucosaminyltransferase III) gene
Porcine CTLA4-Ig (Cytotoxic T-Lymphocyte Antigen 4 or CD152)
Human TRAIL (tumor necrosis factor-alpha-related apoptosis-inducing ligand)
Anticoagulation and anti-inflammatory gene expression or deletion
von Willebrand factor (vWF)-deficient (natural mutant)
Human tissue factor pathway inhibitor (TFPI)
Human thrombomodulin
Human endothelial protein C receptor (EPCR)
Human CD39 (ectonucleoside triphosphate diphosphohydrolase-1)
Anticoagulation, anti-inflammatory, and anti-apoptotic gene expression
Human A20 (tumor necrosis factor-alpha-induced protein 3)
Human heme oxygenase-1 (HO-1)
Human CD47 (species-specific interaction with SIRP-α inhibits phagocytosis)
Porcine asialoglycoprotein receptor 1 gene-knockout (ASGR1-KO) (decreases platelet phagocytosis)
Human signal regulatory protein α (SIRPα) (decreases platelet phagocytosis by ‘self’ recognition)
Prevention of porcine endogenous retrovirus (PERV) activation
PERV siRNA
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